Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2021 | Upfront treatment of ROS1-rearranged NSCLC

Federico Cappuzzo • 22 Mar 2021
ELCC 2021
Lung Cancer Non-Small Cell Lung Cancer Crizotinib Entrectinib Lorlatinib Sunitinib

Federico Cappuzzo, MD, PhD, AUSL della Romagna, Ravenna, Italy, discusses how to choose the optimal therapy for the upfront treatment of ROS1-rearranged non-small cell lung cancer (NSCLC). Dr Cappuzzo outlines the potential benefits and limitations of crizotinib, entrectinib and lorlatinib for patients with ROS1-rearranged NSCLC. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.

More from Federico Cappuzzo

1:25
Current treatment recommendations and future directions for EGFR-mutant NSCLC
Federico Cappuzzo • 7 Aug 2022
1:06
FoRT 05-BEAT: comparing 1L atezolizumab vs atezolizumab + bevacizumab in PD-L1 high NSCLC
Federico Cappuzzo • 7 Aug 2022
1:18
MRD status in lung cancer
Federico Cappuzzo • 7 Aug 2022
1:06
METROS: crizotinib in ROS1+NSCLC long-term OS analysis in patients with brain metastasis
Federico Cappuzzo • 7 Aug 2022

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
0:45
Assessing treatment options for lung cancer with interstitial lung disease
Matthew Hatton • 18 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals